Indian govt mandates price reduction for 3 anti-cancer drugs due to customs duty elimination and GST decrease.

The Indian government has mandated a price reduction for three anti-cancer drugs—Trastuzumab, Osimertinib, and Durvalumab—following the elimination of customs duties and a decrease in Goods and Services Tax (GST) from 12% to 5%. The National Pharmaceutical Pricing Authority (NPPA) instructed manufacturers to adjust Maximum Retail Prices (MRP) and provide updated price lists to relevant authorities, aiming to enhance drug affordability for cancer patients.

October 29, 2024
16 Articles